Clinical trials evaluating AK104 aim to determine its efficacy in PD-1/PD-L1 blockade-resistant MSI-H/dMMR CRC (NCT05426005), as a perioperative treatment for locally advanced MSI-H/dMMR CRC (NCT04556253), and in combination with mFOLFOXIRI in locally advanced CRC (NCT00571644). Here, CD274 is linked to colorectal carcinoma.